OE
AVXL icon

October Effect’s Anavex Life Sciences AVXL Stock Holding History

October Effect’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,250
Closed -$46.8K – 65
2026
Q1 		$46.8K Sell
15,250
-31,030
-67% -$134K 0.05% 64
2025
Q4 		$165K Sell
46,280
-198,941
-81% -$1.22M 0.18% 59
2025
Q3 		$2.18M Buy
245,221
+128,675
+110% +$1.31M 2.41% 12
2025
Q2 		$1.07M Buy
+116,546
New +$995K 1.3% 21

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

October Effect's AVXL Position: Q2 2026 in Review

October Effect sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 15,250 shares — an estimated $46.8K sold.

October Effect first reported a position in AVXL in Q2 2025 and held it in 4 quarters. The position peaked at $2.18M in Q3 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • October Effect reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • October Effect sold 15,250 Anavex Life Sciences shares in Q2 2026, an estimated $46.8K.
  • October Effect first reported a position in Anavex Life Sciences in Q2 2025 and held it in 4 quarters.
  • October Effect's Anavex Life Sciences position peaked at $2.18M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on October Effect's 13F filing for Q2 2026, filed 21 Jul 2026.